SysVASC recognises Intellectual Property (IP) management as an important part of its work plan. To ensure effective collaboration across the entire consortium, a tailored plan for the protection of research results and exploitation of intellectual property rights arising within sysVASC has been developed.
SysVASC has a focus on market know-how, such as detailed similarity maps of animal models to human disease, or identified therapeutic targets as "business-to-business" products to pharmaceutical industry as first customers. The benefit to pharmaceutical industry customers will include access to know-how, sophisticated characterisation of animal models, detailed information on molecular features (potential therapeutic targets) associated with CVD far beyond currently established systems. This know-how might result in major advantages in drug development and (pre)clinical testing.